Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol. 2014;10(3):153–161.
   PubMedGoogle Scholar
• Lu J, Zhang XP, Zhong B-Y, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019;4(9):721–730. doi:10.1016/S2468-1253(19)30178-531387735
   PubMed Web of Science ®Google Scholar
• Gnoni A, Licchetta A, Memeo R, et al. Role of BRAF in hepatocellular carcinoma: a rationale for future targeted cancer therapies. Medicina. 2019;55. doi:10.3390/medicina55120754.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Fut Oncol. 2021;17(7):755–757. doi:10.2217/fon-2020-0986
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021;13(8):637–644. doi:10.2217/imt-2021-002633820447
   PubMed Web of Science ®Google Scholar
• Dai Y, Jiang H, Jiang H, et al. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis. Transl Oncol. 2021;14(12):101238. doi:10.1016/j.tranon.2021.10123834628285
   PubMed Web of Science ®Google Scholar
• Gorodetski B, Chapiro J, Schernthaner R, et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol. 2017;27(2):526–535. doi:10.1007/s00330-016-4445-927277261
   PubMed Web of Science ®Google Scholar
• Park J, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. doi:10.1111/liv.1281825752327
   PubMed Web of Science ®Google Scholar
• Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response‐based approach. Hepatology. 2020;72(1):198–212. doi:10.1002/hep.3102231698504
   PubMed Web of Science ®Google Scholar
• Raoul J-L, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.00230447470
   PubMed Web of Science ®Google Scholar
• Han T, Yang X, Zhang Y, et al. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2019;13(5):374–381. doi:10.5582/bst.2019.0115331611486
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Arizumi T, Allara E, et al. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol. 2015;13:1204–1208.e2. doi:10.1016/j.cgh.2014.11.03725528009
   PubMed Web of Science ®Google Scholar
• Kim BK, Shim JH, Kim SU, et al. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int. 2016;36(1):92–99. doi:10.1111/liv.1286525950442
   PubMed Web of Science ®Google Scholar
• Cappelli A, Cucchetti A, Cabibbo G, et al. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016;36(5):729–736. doi:10.1111/liv.1302926604044
   PubMed Web of Science ®Google Scholar
• Peisen F, Maurer M, Grosse U, et al. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). Eur Radiol. 2020;30(7):3782–3792. doi:10.1007/s00330-020-06734-832125515
   PubMed Web of Science ®Google Scholar
• Park Y, Kim BK, Park JY, et al. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer. 2019;19(1):363. doi:10.1186/s12885-019-5495-630991968
   PubMed Web of Science ®Google Scholar
• Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan. Digest Dis. 2015;33(6):765–770. doi:10.1159/000439101
   PubMed Web of Science ®Google Scholar
• Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–526. doi:10.1093/biomet/81.3.515
   Web of Science ®Google Scholar
• Luo J, Guo R-P, Lai ECH, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18:413–420. doi:10.1245/s10434-010-1321-820839057
   PubMed Web of Science ®Google Scholar
• Lv W-F, Liu K-C, Lu D, et al. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis. Cancer Manag Res. 2018;10:4719–4726. doi:10.2147/CMAR.S16652730410405
   PubMed Web of Science ®Google Scholar
• Liang H, Cui P, Guo Q, et al. Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. Asia Pac J Clin Oncol. 2017;13(5):e331–e341. doi:10.1111/ajco.1260628078806
   PubMed Web of Science ®Google Scholar
• Kim JH, Shim JH, Yoon H-K, Ko H-K, Kim JW, Il Gwon D. Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein. Liver Int. 2018;38(9):1646–1654. doi:10.1111/liv.1371929436101
   PubMed Web of Science ®Google Scholar
• Zhao S-M, Qiu L-W, Zhao H, et al. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors. J Cancer Res Ther. 2021;17(3):707–714. doi:10.4103/jcrt.JCRT_651_2034269303
   PubMed Web of Science ®Google Scholar
• Zhou T-Y, Chen S-Q, Wang H-L, et al. Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres® microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study. J Cancer. 2021;12(15):4522–4529. doi:10.7150/jca.5465034149916
   PubMed Web of Science ®Google Scholar
• Akinwande O, Kim D, Edwards J, et al. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg Oncol. 2015;24(3):270–275. doi:10.1016/j.suronc.2015.06.00826133576
   PubMed Web of Science ®Google Scholar
• Prajapati HJ, Kim HS. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS One. 2017;12(2):e0170750. doi:10.1371/journal.pone.017075028170405
   PubMed Web of Science ®Google Scholar
• Kunutsor SK. Gamma-glutamyltransferase—friend or foe within? Liver Int. 1723–1734;36(2016). doi:10.1111/liv.13221
   Web of Science ®Google Scholar
• Long Y, Zeng F, Shi J, Tian H, Chen T. Gamma-glutamyltransferase predicts increased risk of mortality: a systematic review and meta-analysis of prospective observational studies. Free Radic Res. 2014;48(6):716–728. doi:10.3109/10715762.2014.90205524684379
   PubMed Web of Science ®Google Scholar
• Guo J, Liu S, Gao S, et al. γ-Glutamyltranspeptidase as a prognostic biomarker in advanced hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol. 2021;32(3):419–428.e2. doi:10.1016/j.jvir.2020.07.02033067120
   PubMed Web of Science ®Google Scholar
• Zhang JB, Chen Y, Zhang B, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23(9):787–793. doi:10.1097/MEG.0b013e32834902dd21730869
   PubMed Web of Science ®Google Scholar
• Guiu B, Deschamps F, Boulin M, et al. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 2012;35(5):1102–1108. doi:10.1007/s00270-011-0293-922009578
   PubMed Web of Science ®Google Scholar
• Daubeuf S, Balin D, Leroy P, Visvikis A. Different mechanisms for gamma-glutamyltransferase-dependent resistance to carboplatin and cisplatin. Biochem Pharmacol. 2003;66(4):595–604. doi:10.1016/s0006-2952(03)00343-512906924
   PubMed Web of Science ®Google Scholar